Resveratrol attenuates pulmonary fibrosis by inhibiting alveolar epithelial senescence via targeting SASP-related proteins: an integrated bioinformatics-experimental study
Resveratrol effectively inhibits alveolar epithelial cell senescence and ameliorates pulmonary fibrosis, likely by targeting key senescence-associated pathways (e.g., SERPINE1, MMP2, IL-6). This study provides a promising transdisciplinary strategy for anti-fibrotic drug discovery and highlights RES as a potential therapeutic candidate for PF.
Authors
- Chen Luo (ORCID: https://orcid.org/0000-0002-8897-4293)
- Su Yuan
- Jie Zhou
- Biao Zuo
- Lipeng Shi (ORCID: https://orcid.org/0000-0002-3258-3891)
- Xuqin Du (ORCID: https://orcid.org/0000-0002-6782-4122)
- Yi Ren (ORCID: https://orcid.org/0000-0003-4731-5141)
- Jinxin Chen (ORCID: https://orcid.org/0000-0002-4036-5472)
- Botao Chen (ORCID: https://orcid.org/0000-0003-0740-5652)
- Yaoxin Wu (ORCID: https://orcid.org/0009-0009-2857-4245)
Institutions
- Chongqing University (CN)
- Chongqing Jiulongpo People's Hospital (CN)
- First People's Hospital of Chongqing (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.3389/fphar.2025.1680998
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China